종합 밸류에이션 구간 · 보수적 $170–$190 / 적정 $276–$374 / 낙관적 $466–$510. $282.44 기준, 적정 내재가치 구간 내.
보고서 발행 시 $297.09（2026년 7월 2일）
WSJ reported Elliott built a sizable Bio-Rad stake and plans to push for improved share performance.
Possible impact:May affect expectations for governance changes, asset value realization and possible strategic actions.
Automatically summarized from public sources; for context only, not investment advice.
데이터 제공: EODHD, 보고 통화 기준 표시. 참고용일 뿐 투자 자문이 아닙니다.
Bio-Rad Laboratories, Inc. develops, manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, Latin America, and internationally. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantify biological materials, including cells, proteins, and nucleic acids used in research and biopharmaceutical laboratory environments, as well as for biopharmaceutical manufacturing, quality control process, food safety, and science education applications. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology companies, food producers, and testing laboratories. Its Clinical Diagnostics segment designs, manufactures, markets, and supports diagnostic test systems, informatics systems, test kits, and specialized quality controls for clinical, hospital, diagnostic reference, and transfusion and physician office laboratories, as well as software. The company offers its products through its direct commercial organization, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
준비 중이 섹션은 작성 중입니다. 곧 다시 확인해 주세요.
준비 중이 섹션은 작성 중입니다. 곧 다시 확인해 주세요.
이 종목에 대한 리포트가 아직 해당 언어로 없습니다.
